Explore a selection of our essential drug information below, or:
Overview
- Description
- A laxative used to clear the colon before a colonoscopy.
- Description
- A laxative used to clear the colon before a colonoscopy.
- DrugBank ID
- DB14502
- Type
- Small Molecule
- Clinical Trials
- Phase 0
- 0
- Phase 1
- 2
- Phase 2
- 8
- Phase 3
- 4
- Phase 4
- 7
- Mechanism of Action
- Carbonic anhydrase 4Inhibitor
- Carbonic anhydrase 4
Identification
- Summary
Sodium phosphate, dibasic is an osmotic laxative used to cleanse the colon before a colonoscopy.
- Brand Names
- Bss Ophthalmic Solution, Fleet Mineral Oil, Glycerolyte 57, Isolyte S pH 7.4, K-phos Neutral, Osmoprep, Pedia-lax Liquid, Phoxillum, Tis-U-sol
- Generic Name
- Sodium phosphate, dibasic
- DrugBank Accession Number
- DB14502
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Sodium phosphate, dibasic (DB14502)
- Weight
- Average: 141.9588
Monoisotopic: 141.940784382 - Chemical Formula
- HNa2O4P
- Synonyms
- Dibasic sodium phosphate anhydrous
- Dibasic sodium phosphate, anhydrous
- Disodium acid phosphate
- Disodium hydrogen monophosphate
- Disodium hydrogen phosphate
- Disodium hydrogen phosphate, anhydrous
- disodium hydrogenphosphate
- Disodium phosphate
- Phosphoric acid, disodium salt, anhydrous
- Phosphoric acid, sodium salt (1:2)
- Sodium phosphate dibasic
- Sodium phosphate, dibasic
- Sodium phosphate, dibasic (anhydrous)
- Sodium phosphate, dibasic anhydrous
- Sodium phosphate, dibasic, anhydrous
- Sodium phosphate,dibasic,anhydrous
- External IDs
- E-339(II)
- Fema no. 2398
- INS NO.339(II)
- INS-339(II)
Pharmacology
- Indication
Used to treat constipation or to clean the bowel before a colonoscopy Label.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Constipation Combination Product in combination with: Glycerin (DB09462), Sodium phosphate, monobasic (DB09449) ••• ••• ••••• Used in combination to treat Hypophosphatemia Combination Product in combination with: Monopotassium phosphate (DB09413), Sodium phosphate, monobasic (DB09449) •••••••••••• ••••••• •••••• Used in combination to treat Severe constipation Combination Product in combination with: Sodium phosphate, monobasic (DB09449) •••••••••••• •••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Sodium phosphate inceases fecal water content to increase mobility through the large intestine 1.
- Mechanism of action
Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen 1.
Target Actions Organism ACarbonic anhydrase 4 inhibitorHumans - Absorption
Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h 3.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats 7. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma 4. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients 3.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Sodium phosphate, dibasic. Aclidinium The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Alfentanil. Alloin The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Alloin. Almasilate The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Almasilate. - Food Interactions
- Take with a full glass of water.
- Take with food.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Sodium phosphate, dibasic dihydrate 94255I6E2T 10028-24-7 KDQPSPMLNJTZAL-UHFFFAOYSA-L Sodium phosphate, dibasic dodecahydrate E1W4N241FO 10039-32-4 DGLRDKLJZLEJCY-UHFFFAOYSA-L Sodium phosphate, dibasic, heptahydrate 70WT22SF4B 7782-85-6 PYLIXCKOHOHGKQ-UHFFFAOYSA-L Sodium phosphate, dibasic, monohydrate BWZ7K44R51 118830-14-1 LVXHNCUCBXIIPE-UHFFFAOYSA-L - Active Moieties
Name Kind UNII CAS InChI Key Sodium cation ionic LYR4M0NH37 17341-25-2 FKNQFGJONOIPTF-UHFFFAOYSA-N Phosphate ion ionic NK08V8K8HR 14265-44-2 NBIIXXVUZAFLBC-UHFFFAOYSA-K - Product Images
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Aminoplasmal B. Braun 10%E Solution for Intravenous Infusion Sodium phosphate, dibasic dodecahydrate (3.581 g/1000ml) + Alanine (10.5 g/1000ml) + Arginine (11.5 g/1000ml) + Aspartic acid (5.6 g/1000ml) + Glutamic acid (7.2 g/1000ml) + Glycine (12 g/1000ml) + Histidine (3 g/1000ml) + Isoleucine (5 g/1000ml) + Leucine (8.9 g/1000ml) + Lysine hydrochloride (8.56 g/1000ml) + Magnesium chloride hexahydrate (0.508 g/1000ml) + Methionine (4.4 g/1000ml) + Phenylalanine (4.7 g/1000ml) + Potassium acetate (2.453 g/1000ml) + Proline (5.5 g/1000ml) + Serine (2.3 g/1000ml) + Sodium acetate trihydrate (2.858 g/1000ml) + Sodium hydroxide (0.36 g/1000ml) + Threonine (4.2 g/1000ml) + Tryptophan (1.6 g/1000ml) + Tyrosine (0.4 g/1000ml) + Valine (6.2 g/1000ml) Injection, solution Intravenous B.BRAUN MEDICAL INDUSTRIES SDN. BHD. 2020-09-08 Not applicable Malaysia 
AMINOPLASMAL B.BRAUN 10% E SOLUTION FOR INFUSION Sodium phosphate, dibasic dodecahydrate (3.581 g/1000ml) + Alanine (10.50 g/1000ml) + Arginine (11.50 g/1000ml) + Aspartic acid (5.60 g/1000ml) + Glutamic acid (7.20 g/1000ml) + Glycine (12.00 g/1000ml) + Histidine (3.00 g/1000ml) + Isoleucine (5.00 g/1000ml) + Leucine (8.90 g/1000ml) + Lysine hydrochloride (8.56 g/1000ml) + Magnesium chloride hexahydrate (0.508 g/1000ml) + Methionine (4.40 g/1000ml) + Phenylalanine (4.70 g/1000ml) + Potassium acetate (2.453 g/1000ml) + Proline (5.50 g/1000ml) + Serine (2.30 g/1000ml) + Sodium acetate trihydrate (2.858 g/1000ml) + Sodium hydroxide (0.360 g/1000ml) + Threonine (4.20 g/1000ml) + Tryptophan (1.60 g/1000ml) + Tyrosine (0.40 g/1000ml) + Valine (6.20 g/1000ml) Solution Intravenous B. BRAUN SINGAPORE PTE LTD 2018-01-23 Not applicable Singapore 
AMINOPLASMAL® 10% E Sodium phosphate, dibasic dodecahydrate (3.581 g) + Alanine (10.5 g) + Arginine (11.5 g) + Aspartic acid (5.6 g) + Glutamic acid (7.2 g) + Glycine (12 g) + Histidine (3 g) + Isoleucine (5 g) + Leucine (8.9 g) + Lysine hydrochloride (8.56 g) + Magnesium chloride hexahydrate (0.508 g) + Phenylalanine (4.7 g) + Potassium acetate (2.453 g) + Proline (5.5 g) + Racemethionine (4.4 g) + Serine (2.3 g) + Sodium acetate trihydrate (2.858 g) + Sodium hydroxide (0.36 g) + Threonine (4.2 g) + Tryptophan (1.6 g) + Tyrosine (0.4 g) + Valine (6.2 g) Solution Intravenous B. Braun Medical Inc. 2015-07-27 Not applicable Colombia 
Aminosyn II 7% M In 10% Dextrose(dual Chamber) Sodium phosphate, dibasic (49 mg / 100 mL) + Alanine (348 mg / 100 mL) + Arginine (356 mg / 100 mL) + Aspartic acid (245 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL) + Glutamic acid (258 mg / 100 mL) + Glycine (175 mg / 100 mL) + Histidine (105 mg / 100 mL) + Isoleucine (231 mg / 100 mL) + Leucine (350 mg / 100 mL) + Lysine acetate (368 mg / 100 mL) + Magnesium chloride (30 mg / 100 mL) + Methionine (60 mg / 100 mL) + N-acetyltyrosine (94 mg / 100 mL) + Phenylalanine (104 mg / 100 mL) + Potassium chloride (97 mg / 100 mL) + Proline (252 mg / 100 mL) + Serine (186 mg / 100 mL) + Sodium chloride (120 mg / 100 mL) + Threonine (140 mg / 100 mL) + Tryptophan (70 mg / 100 mL) + Valine (175 mg / 100 mL) Solution Intravenous Hospira Healthcare Ulc 1987-12-31 2012-08-03 Canada 
Aminosyn II 8.5% M In 20% Dextrose (dual Chamber) Sodium phosphate, dibasic (49 mg / 100 mL) + Alanine (422 mg / 100 mL) + Arginine (432 mg / 100 mL) + Aspartic acid (298 mg / 100 mL) + Dextrose, unspecified form (10 g / 100 mL) + Glutamic acid (314 mg / 100 mL) + Glycine (212 mg / 100 mL) + Histidine (128 mg / 100 mL) + Isoleucine (280 mg / 100 mL) + Leucine (425 mg / 100 mL) + Lysine acetate (446 mg / 100 mL) + Magnesium chloride (30 mg / 100 mL) + Methionine (73 mg / 100 mL) + N-acetyltyrosine (115 mg / 100 mL) + Phenylalanine (126 mg / 100 mL) + Potassium chloride (97 mg / 100 mL) + Proline (307 mg / 100 mL) + Serine (225 mg / 100 mL) + Sodium chloride (120 mg / 100 mL) + Threonine (170 mg / 100 mL) + Tryptophan (85 mg / 100 mL) + Valine (212 mg / 100 mL) Solution Intravenous Hospira Healthcare Ulc 1987-12-31 2012-08-03 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image B.T.ENEMA 210 ML LAVMAN Sodium phosphate, dibasic (3.5 g/59ml) + Sodium phosphate, monobasic (9.5 g/59ml) Enema Rectal YENİŞEHİR LABORATUARI LTD. ŞTİ. 2013-01-29 2022-04-11 Turkey 
B.T.ENEMA 67,5 ML LAVMAN Sodium phosphate, dibasic (3.5 g/59ml) + Sodium phosphate, monobasic (9.5 g/59ml) Enema Rectal YENİŞEHİR LABORATUARI LTD. ŞTİ. 2013-01-29 2022-04-11 Turkey Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) Tablet Oral Avera McKennan Hospital 2015-03-11 2017-05-24 US 
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) Tablet Oral Rising Pharma Holdings, Inc. 2012-06-28 Not applicable US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) Tablet Oral KAISER FOUNDATION HOSPITALS 2014-07-07 2018-01-31 US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkali metal oxoanionic compounds
- Sub Class
- Alkali metal phosphates
- Direct Parent
- Alkali metal phosphates
- Alternative Parents
- Inorganic sodium salts / Inorganic oxides
- Substituents
- Alkali metal phosphate / Inorganic oxide / Inorganic salt / Inorganic sodium salt
- Molecular Framework
- Not Available
- External Descriptors
- sodium phosphate (CHEBI:34683)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 22ADO53M6F
- CAS number
- 7558-79-4
- InChI Key
- BNIILDVGGAEEIG-UHFFFAOYSA-L
- InChI
- InChI=1S/2Na.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2
- IUPAC Name
- disodium hydrogen phosphate
- SMILES
- [Na+].[Na+].OP([O-])([O-])=O
References
- General References
- Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24. [Article]
- Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521. [Article]
- Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27. [Article]
- Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377. [Article]
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- FDA Guide: Sodium Phosphate Tablet [Link]
- ChemIDPlus: Sodium Phosphate [Link]
- External Links
- KEGG Compound
- C13558
- ChemSpider
- 22625
- ChEBI
- 34683
- ChEMBL
- CHEMBL1060
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Approved for Marketing Not Available Bowel Gass Passage / Postoperative Bowel Sounds 1 somestatus stop reason just information to hide Not Available Completed Other Laparoscopic Hysterectomy and/or Laparoscopic Sacrocolpopexy 1 somestatus stop reason just information to hide Not Available Completed Prevention Human Immunodeficiency Virus (HIV) Infections 1 somestatus stop reason just information to hide Not Available Unknown Status Not Available Colon Cancer 1 somestatus stop reason just information to hide Not Available Unknown Status Treatment Angle-Closure Glaucoma / Glaucoma, Closed-Angle / Narrow-angle glaucoma 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intravenous 10.50 g/1000ml Solution Intravenous Injection, solution Intravenous Powder, for solution Intraocular Solution Hemodialysis; Intravenous Solution Hemodialysis; Intravenous 0.187 g/L Kit; solution Intraocular Solution, concentrate Rectal Solution Rectal Liquid Oral Kit Intravenous Solution Unknown Tablet, coated Oral Solution Oral Liquid Buccal Spray Buccal Kit; solution Intraocular; Irrigation Liquid Topical Tablet, effervescent Oral Emulsion Intravenous Emulsion Parenteral Tablet Oral Solution Oral 1.2 g/5ml Solution Hemodialysis Injection Intravenous Enema Rectal Solution Respiratory (inhalation) Injection, solution, concentrate Intravenous Powder Oral Solution Oral 0.9 g/5ml Irrigant Irrigation Solution Irrigation Liquid Irrigation Syrup Solution - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US7687075 No 2010-03-30 2028-06-22 US
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -1 Chemaxon pKa (Strongest Acidic) 1.8 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 83.42 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 12.41 m3·mol-1 Chemaxon Polarizability 5.24 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 106.69356 predictedDeepCCS 1.0 (2019) [M+H]+ 109.840004 predictedDeepCCS 1.0 (2019) [M+Na]+ 118.66112 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Catalyzes the reversible hydration of carbon dioxide into bicarbonate and protons and thus is essential to maintaining intracellular and extracellular pH (PubMed:15563508, PubMed:16686544, PubMed:16807956, PubMed:17127057, PubMed:17314045, PubMed:17652713, PubMed:17705204, PubMed:18618712, PubMed:19186056, PubMed:19206230, PubMed:7625839). May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis (PubMed:15563508). It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid (PubMed:15563508)
- Specific Function
- carbonate dehydratase activity
- Gene Name
- CA4
- Uniprot ID
- P22748
- Uniprot Name
- Carbonic anhydrase 4
- Molecular Weight
- 35032.075 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Sodium-phosphate symporter which preferentially transports the monovalent form of phosphate with a stoichiometry of two sodium ions per phosphate ion (PubMed:11009570, PubMed:16790504, PubMed:17494632, PubMed:19726692, PubMed:7929240, PubMed:8041748). May play a role in extracellular matrix and cartilage calcification as well as in vascular calcification (PubMed:11009570). Essential for cell proliferation but this function is independent of its phosphate transporter activity (PubMed:19726692)
- Specific Function
- high-affinity phosphate
- Gene Name
- SLC20A1
- Uniprot ID
- Q8WUM9
- Uniprot Name
- Sodium-dependent phosphate transporter 1
- Molecular Weight
- 73699.01 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Sodium-phosphate symporter which preferentially transports the monovalent form of phosphate with a stoichiometry of two sodium ions per phosphate ion (PubMed:12205090, PubMed:15955065, PubMed:16790504, PubMed:17494632, PubMed:22327515, PubMed:28722801, PubMed:30704756). Plays a critical role in the determination of bone quality and strength by providing phosphate for bone mineralization (By similarity). Required to maintain normal cerebrospinal fluid phosphate levels (By similarity). Mediates phosphate-induced calcification of vascular smooth muscle cells (VCMCs) and can functionally compensate for loss of SLC20A1 in VCMCs (By similarity)
- Specific Function
- phosphate transmembrane transporter activity
- Gene Name
- SLC20A2
- Uniprot ID
- Q08357
- Uniprot Name
- Sodium-dependent phosphate transporter 2
- Molecular Weight
- 70391.755 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane (PubMed:12324554, PubMed:20335586, PubMed:26047794, PubMed:8327470). The cotransport has a Na(+):Pi stoichiometry of 3:1 and is electrogenic (By similarity)
- Specific Function
- identical protein binding
- Gene Name
- SLC34A1
- Uniprot ID
- Q06495
- Uniprot Name
- Sodium-dependent phosphate transport protein 2A
- Molecular Weight
- 68936.53 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Involved in actively transporting phosphate into cells via Na(+) cotransport
- Specific Function
- phosphate ion binding
- Gene Name
- SLC34A2
- Uniprot ID
- O95436
- Uniprot Name
- Sodium-dependent phosphate transport protein 2B
- Molecular Weight
- 75758.535 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane (PubMed:11880379). The cotransport has a Na(+):Pi stoichiometry of 2:1 and is electroneutral (By similarity)
- Specific Function
- sodium
- Gene Name
- SLC34A3
- Uniprot ID
- Q8N130
- Uniprot Name
- Sodium-dependent phosphate transport protein 2C
- Molecular Weight
- 63548.94 Da
References
- Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [Article]
Drug created at July 11, 2018 17:31 / Updated at August 26, 2024 19:22